Stocklytics Platform
Asset logo for symbol NVAX
Novavax
NVAX65
$9.11arrow_drop_up1.90%$0.16
Asset logo for symbol NVAX
NVAX65

$9.11

arrow_drop_up1.90%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Novavax (NVAX) Stocklytics Forecast

Novavax Inc (NVAX) is a biotechnology company that specializes in the research, development, and commercialization of vaccines. With a strong focus on respiratory diseases, Novavax has made significant strides in the fight against infectious diseases. As the world grapples with the ongoing COVID-19 pandemic, Novavax has emerged as a key player in the race to develop an effective vaccine. Given the company's track record and dedication to innovation, many analysts and experts believe that Novavax stock has the potential for substantial growth in the coming years.
When it comes to predicting the future price of Novavax Inc (NVAX) stock, various factors come into play. One approach to forecasting stock prices involves using artificial intelligence (AI) algorithms. AI-based prediction models analyze historical stock data, market trends, and other relevant factors to generate forecasts. According to these AI models, Novavax Inc (NVAX) stock is expected to experience steady growth in the next few years. The forecasts suggest that the stock price could reach new heights by 2023, making it an attractive investment opportunity.
add Novavax  to watchlist

Keep an eye on Novavax

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Novavax (NVAX) stock?

Analysts have set a target price of $173.9 for Novavax (NVAX), based on forecasts from 21 analysts. The predicted price range extends from a high of $397 to a low of $10. This represents a potential increase of up to 4.26K% and a decrease of 9.71% from the current price of $9.12. These forecasts are as of 2020 Nov 25.
help

What are the analyst ratings for Novavax (NVAX) stock?

The analyst ratings for Novavax (NVAX) are distributed as follows: 3 analysts recommend buying, 2 have a neutral stance, and 1 suggest selling. The prevailing sentiment among the total of 6 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Novavax .
help

What is the AI price prediction for Novavax (NVAX) stock?

At present, there is no AI or machine-learning-based price prediction available for Novavax (NVAX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level